Application No. 10/580,588 Paper Dated January 17, 2008 Attorney Docket No. 3824-061668

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.

10/580,588

Applicants

Yutaka Sashida et al.

Filed

May 25, 2006

Title

Novel Compound and Pharmaceutical Composition

Art Unit

1614

Examiner Name

Not Yet Assigned

Confirmation No.

5444

Customer No.

28289

MAIL STOP AMENDMENT Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the requirements of 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby submit this Information Disclosure Statement (IDS), together with completed Form PTO/SB/08a, Form PTO/SB/08b and a copy of each reference listed thereon.

I hereby certify that this correspondence is being deported United States Postal Service as First Class Mail in addressed to Commissioner for Patents, P.O. Alexandria, VA 22313-1450 on January 17, 2008.	an envelope
Bruce L. White (Name of Person Mailing Paper or Fee)	
Brue L White	01/17/2008
Signature	Date

Application No. 10/580,588 Paper Dated January 17, 2008 Attorney Docket No. 3824-061668

The above-identified application is the U.S. national phase of PCT/JP2004/017480, filed November 25, 2004.

Some of the references listed on PTO/SB/08a were cited in an International Search Report (ISR), dated April 5, 2005 and/or an International Preliminary Report on Patentability (IPRP), dated August 3, 2006 in the corresponding PCT application. Copies of the ISR and IPRP are enclosed herewith.

Some of the references listed on PTO/SB/08a were cited in Office Actions in one of the priority Japanese patent applications. Copies of the Japanese Office Actions are enclosed herewith. English-language abstracts of the references cited by the Japanese Office Actions are also enclosed herewith.

Some of the references listed on Form PTO/SB/08a and Form PTO/SB/08b are cited in the specification of the application at page 1 and page 6, and are relevant for the reasons discussed therein.

Since this Information Disclosure Statement is being submitted before the mailing date of a first Office Action on the merits, it is timely under 37 C.F.R. §1.97(b)(3) and no fee is required. The Commissioner of Patents and Trademarks is hereby authorized to charge any additional fees which may be required to Deposit Account No. 23-0650. One (1) original and two (2) copies of this Information Disclosure Statement are enclosed.

Bv

Respectfully submitted,

THE WEBB LAW FIRM

) What h Chyn Richard L. Byrne

Registration No. 28,498

Attorney for Applicants

700 Koppers Building

436 Seventh Avenue

Pittsburgh, Pennsylvania 15219

Telephone: 412-471-8815

Facsimile: 412-471-4094

E-mail: Webblaw@webblaw.com